214147-48-5|1-(4-Aminopiperidin-1-yl)ethanone hydrochloride| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 214147-48-5 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 214147-48-5 ]

CAS No. :	214147-48-5
Formula :	C₇H₁₅ClN₂O
M.W :	178.66
SMILES Code :	CC(N1CCC(N)CC1)=O.[H]Cl
MDL No. :	MFCD08690151
InChI Key :	AWKOGAFRLOPNOP-UHFFFAOYSA-N
Pubchem ID :	17221642

Safety of [ 214147-48-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 214147-48-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	0
Fraction Csp3	0.86
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	50.33
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	46.33 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.14
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.38
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.28
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.07
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.17

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-0.97
Solubility	19.1 mg/ml ; 0.107 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-0.67
Solubility	38.2 mg/ml ; 0.214 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.33
Solubility	84.3 mg/ml ; 0.472 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.29 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.2

Application In Synthesis of [ 214147-48-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 214147-48-5 ]

[ 214147-48-5 ] Synthesis Path-Downstream 1~20

2
[ 214147-48-5 ]
[ 675111-82-7 ]
4-[(1-acetylpiperidin-4-yl)amino]-1-ethyl-N-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		A solution of Intermediate 22 (0. [03G,] ca. 0.1 mmol) in ethanol [(LML)] was treated with triethylamine (0. [07ML,] 0.5 mmol), followed by a 0. 1M ethanolic solution of Intermediate 6 [(L.] [LML OF THE] solution [= 0.] 11 mmol). The mixture was heated at reflux [(80C)] for 18h. A further portion of Intermediate 6 [(0.] [OLML,] undiluted) was then added and heating continued for a further 24h. Volatiles were removed in vacuo and the residue dissolved in DCM, then applied to an SPE cartridge (aminopropyl, [I G) WHICH] was eluted first with DCM, then with methanol. The DCM fraction was concentrated in vacuo, then applied to an SPE cartridge (silica, [0.] 5g) eluting with [(I)] DCM, (ii) EtOAc and (iii) a stepwise gradient of chloroform: methanol (from 99: 1 up to 4: 1). Fractions containing desired material were combined to afford Example 57 (0. 003g). LCMS showed MH+ = 422; [TRET] = 2. 1min.

References: [1]Patent: WO2004/24728,2004,A2 .Location in patent: Page 159.

3
[ 214147-48-5 ]
[ 675111-93-0 ]
4-[(1-acetylpiperidin-4-yl)amino]-N-benzyl-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		A solution of Intermediate [28] (0. [03G,] 0.1 mmol) in ethanol [(LML)] was treated with a [0.] 1M ethanolic solution of Intermediate 6 [(L.] lml of solution [= 0.] 11 mmol). Triethylamine (0. [07ML,] 0.5 mmol) was then added and the mixture heated at reflux [(85C),] under nitrogen for 12h. A further portion of Intermediate 6 (0.1 mmol) was then added and heating continued for a further 36h. The mixtures were concentrated in vacuo and the residue treated with chloroform. A small amount of insoluble material was collected by filtration, then the filtrate applied to an SPE cartridge (aminopropyl, [1 G)] which was eluted first with DCM, then with methanol. Fractions containing desired material were combined and concentrated in vacuo. The residue was further purified by SPE (silica, [0.] 5g) eluting with (i) DCM, (ii) chloroform, (iii) EtOAc and (iv) a stepwise gradient of chloroform: methanol (from 99: 1 up to 4: 1). Fractions containing desired material were combined to afford Example 74 (0.029g). LCMS showed MH+ = 407; TRET = 2.57 min.

References: [1]Patent: WO2004/24728,2004,A2 .Location in patent: Page 161.

4
[ 214147-48-5 ]
[ 30720-25-3 ]
ethyl 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 85℃; for 34h;	Intermediate 1 (2.58g), Intermediate 6 (2. [0G)] and N, N-diisopropylethylamine (8. [9ML)] were dissolved in acetonitrile (98ml). The reaction mixture was heated at [85 C] for 24h then an additional portion of Intermediate 6 (0. [18G)] was added and heating continued for a further [L OH.] The reaction was concentrated in vacuo and the residues partitioned between DCM and water. The phases were separated and the organic phase evaporated in vacuo. The residue was purified by chromatography using Biotage (silica 90g) eluting with DCM: MeOH (5%) to afford Example 207 [(1.] 55g) as a white solid. LCMS showed MH+ 360; TROT= 2.71 min.

References: [1]Patent: WO2004/24728,2004,A2 .Location in patent: Page 188.

5
[ 214147-48-5 ]
[ 20951-01-3 ]
[ 283167-09-9 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; triethylamine; In 1,4-dioxane; methanol; dichloromethane; chloroform;	EXAMPLE 9 To a solution of O-phenyl N-(4-pyridyl)carbamate (0.81 g) in chloroform (10 ml) were added <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (0.68 g) and triethylamine (1.06 ml) at ambient temperature. After stirring for 1 day, the mixture changed to a solution. The solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 100 ml, dichloromethane:methanol=10:1 to 5:1, and silica gel 50 ml, dichloromethane:methanol:aqueous ammonia=10:1:0.1). The solvents of desired fractions were removed under reduced pressure. A residue was dissolved with methanol (5 ml) and dichloromethane (5 ml), and 4N hydrogen chloride in dioxane (1.5 ml) was added to the solution. The solvents were removed under reduced pressure, and the residue was evaporated azeotropically with methanol. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-pyridyl)urea (343 mg) was obtained. NMR (DMSO-d6, delta): 1.1-1.6 (2H, m), 1.77 (2H, m), 2.01 (3H, s), 2.94 (1H, br t, J=10.4 Hz), 3.22 (1H, br t, J=10.1 Hz), 3.76 (2H, m), 4.05 (1H, d, J=13.6 Hz), 7.60 (1H, d, J=7.8 Hz), 7.83 (2H, d, J=6.8 Hz), 8.52 (2H, d, J=7.1 Hz), 11.21 (1H, s), 14.66 (1H, br s)

References: [1]Patent: US2004/14745,2004,A1 .

6
[ 214147-48-5 ]
[ 403-43-0 ]
N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane;	EXAMPLE 6 To a suspension of <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (715 mg) in dichloromethane (7 ml) were added diisopropylethylamine (1.83 ml) and a solution of 4-fluorobenzoyl chloride (0.83 mg) in dichloromethane (2 ml) at ambient temperature. After stirring for 6.5 hours, the reaction mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol=50:1 to 10:1). After rinse with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide (738 mg) was obtained. NMR (DMSO-d6, delta): 1.40 (2H, m), 1.81 (2H, distorted t, J=12.4 Hz), 2.01 (3H, s), 2.68 (1H, br t, J=11.4 Hz), 3.13 (1H, br t, J=11.6 Hz), 3.83 (1H, br t, J=13.9 Hz), 4.01 (1H, m), 4.33 (1H, br d, J=13.7 Hz), 7.29 (2H, t, J=8.9 Hz), 7.92 (2H, dd, J=5.5, 8.8 Hz), 8.31 (1H, d, J=7.7 Hz)

References: [1]Patent: US2004/14745,2004,A1 .

7
[ 214147-48-5 ]
[ 1195-45-5 ]
[ 283167-10-2 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane;	EXAMPLE 10 To a suspension of <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (536 mg) in dichloromethane (5 ml) were added 4-fluorophenyl isocyanate (375 mul) and diisopropylethylamine (575 mul) at ambient temperature. After stirring for 3 hours, the reaction mixture was diluted with dichloromethane. An organic phase was separated and an aqueous phase was extracted with dichloromethane. A combined organic phase was dried over magnesium sulfate and the solvents were removed under reduced pressure. After crystallization from diisopropyl ether and n-hexane, N-(1-acetylpiperidin-4-yl)-N'-(4-fluorophenyl)urea (448 mg) was obtained. NMR (DMSO-d6, delta): 1.1-1.5 (2H, m), 1.80 (2H, distorted t, J=10 Hz), 2.00 (3H, s), 2.77 (1H, br d, J=10.8 Hz), 3.14 (1H, br d, J=11.1 Hz), 3.5-3.9 (2H, m), 4.16 (1H, br d, J=13.2 Hz), 6.15 (1H, d, J=7.6 Hz), 7.05 (2H, t, J=8.9 Hz), 7.40 (2H, dd, J=5.0, 9.2 Hz), 8.37 (1H, s)

References: [1]Patent: US2004/14745,2004,A1 .

8
[ 214147-48-5 ]
[ 38377-38-7 ]
[ 283167-05-5 ]

Yield	Reaction Conditions	Operation in experiment
	In pyridine; hydrogenchloride; dichloromethane; water; ethyl acetate;	EXAMPLE 5 To a suspension of <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (0.4 g) in dichloromethane (5 ml) were added in turn pyridine (0.54 ml) and 4-fluorophenyl chloroformate (0.29 ml) at 0 C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour, which was taken up into a mixture of water and ethyl acetate. The separated organic layer was washed in turn with hydrochloric acid (1N), aqueous sodium hydrogen carbonate, and brine, and dried over magnesium sulfate. Evaporation under reduced pressure gave a residue, which was triturated with diisopropyl ether to give 1-acetyl-4-(4-fluorophenoxycarbonylamino)piperidine (347 mg). NMR (DMSO-d6, delta): 1.15-1.55 (2H, m), 1.7-1.95 (2H, m), 2.00 (3H, s), 2.65-2.85 (1H, m), 3.0-3.25 (1H, m), 3.5-3.7 (1H, m), 3.7-3.9 (1H, m), 4.15-4.3 (1H, m), 7.05-7.3 (4H, m), 7.86 (1H, d, J=8 Hz)

References: [1]Patent: US2004/14745,2004,A1 .

9
[ 214147-48-5 ]
[ 349-88-2 ]
N-(1-acetylpiperidin-4-yl)-4-fluorobenzenesulfonamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane;	EXAMPLE 8 To a suspension of <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (715 mg) in dichloromethane (7 ml) were added diisopropylethylamine (1.83 ml) and a solution of 4-fluorobenzenesulfonyl chloride (0.83 mg) in dichloromethane (2 ml) at ambient temperature. After stirring for 6.5 hours, the reaction mixture was diluted with dichloromethane and washed with water, saturated aqueous sodium hydrogen carbonate, and brine. After drying with magnesium sulfate, the solvents were removed under reduced pressure. A residue was purified by column chromatography (silica gel 50 ml, dichloromethane:methanol=50:1 to 20:1). After rinse with diisopropyl ether, N-(1-acetylpiperidin-4-yl)-4-fluorobenzenesulfonamide (859 mg) was obtained. NMR (DMSO-d6, delta): 1.21 (2H, m), 1.54 (2H, m), 1.94 (3H, s), 2.66 (1H, br t, J=10.8 Hz), 3.02 (1H, dt, J=2.9, 12.0 Hz), 3.22 (1H, m), 3.64 (1H, br d, J=14.0 Hz), 4.05 (1H, br d, J=13.2 Hz), 7.44 (2H, t, J=8.9 Hz), 7.8-8.0 (3H, m)

References: [1]Patent: US2004/14745,2004,A1 .

10
[ 214147-48-5 ]
C₁₀H₁₀FNO₅ [ No CAS ]
C₁₇H₂₃N₃O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 48h;	A mixture of aryl halide intermediate VII.2 (10.5 g; 41.9 mmol), the amine <strong>[214147-48-5]1-acetyl-4-aminopiperidine hydrochloride</strong> (7.48 g; 41.9 mmol), potassium carbonate (20.3 g; 147 mmol) and DMF (60 ml) is stirred at r.t. for 2 days. The mixture is diluted with water and extracted with DCM. The organic layer is separated, dried and evaporated. The residue is purified by silica gel chromatography (cyclohexane/ethyl acetate 70:30->20:80) to yield the title compound. [0171] C17H23N3O6 ESI Mass spectrum: m/z=366 [M+H]+
	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 48h;	Intermediate IV.1 A mixture of aryl halide intermediate VII.2 (10.5 g; 41.9 mmol), the amine 1 -acetyl-4- aminopiperidine hydrochloride (7.48 g; 41 .9 mmol), potassium carbonate (20.3 g; 147 mmol) and DMF (60 ml) is stirred at r.t. for 2 days. The mixture is diluted with water and extracted with DCM. The organic layer is separated, dried and evaporated. The residue is purified by silica gel chromatography (cyclohexane / ethyl acetate 70:30 -> 20:80) to yield the title compound. C17H23N3O6 ESI Mass spectrum: m/z = 366 [M+H]+

References: [1]Patent: US2015/18315,2015,A1 .Location in patent: Paragraph 0170-0171.
[2]Patent: WO2015/7517,2015,A1 .Location in patent: Page/Page column 33.

11
[ 73874-95-0 ]
[ 214147-48-5 ]